Head-To-Head Contrast: Pluri (NASDAQ:PLUR) versus Tevogen Bio (NASDAQ:TVGN)

Tevogen Bio (NASDAQ:TVGN) and Pluri (NASDAQ:PLUR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk and institutional ownership.

Analyst Ratings

This is a breakdown of recent recommendations for Tevogen Bio and Pluri, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tevogen Bio	0	0	1	0	3.00
Pluri	0	0	0	0	N/A

Tevogen Bio presently has a consensus target price of $4.20, indicating a potential upside of 493.47%. Given Tevogen Bio’s higher possible upside, research analysts clearly believe Tevogen Bio is more favorable than Pluri.

Risk and Volatility

Tevogen Bio has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500. Comparatively, Pluri has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500.

Profitability

This table compares Tevogen Bio and Pluri’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tevogen Bio	N/A	-273.73%	229.30%
Pluri	-6,339.59%	-248.48%	-49.90%

Insider and Institutional Ownership

16.6% of Pluri shares are held by institutional investors. 56.6% of Tevogen Bio shares are held by insiders. Comparatively, 10.2% of Pluri shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Tevogen Bio and Pluri’s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tevogen Bio	N/A	N/A	-$70,000.00	N/A	N/A
Pluri	$290,000.00	101.29	-$28.32 million	($4.13)	-1.32

Tevogen Bio has higher earnings, but lower revenue than Pluri.

Summary

Tevogen Bio beats Pluri on 6 of the 10 factors compared between the two stocks.

About Tevogen Bio

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.

About Pluri

Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.